This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Hagens Berman Sobol Shapiro LLP Lawsuit: Fresenius Medical Care And DaVita Healthcare Partners Liable For GranuFlo And NaturaLyte Deaths

SEATTLE, March 6, 2013 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a law firm with experience prosecuting cases against healthcare providers and the pharmaceutical industry, today filed two lawsuits in Federal Court in Colorado alleging that DaVita Healthcare Partners, Inc.'s (NYSE: DVA) ("DaVita") actions led to the deaths of two dialysis patients. The lawsuits further allege that the problems that caused those deaths have impacted thousands of dialysis patients across the country, and seek class action status.

The suits claim that DaVita – one of the nation's largest providers of dialysis services – failed to recognize that part of the treatment it used in dialysis was causing dangerously high levels of bicarbonates in the patients, which the suit claims caused the deaths of the two patients cited in the suits, and potentially many other unreported deaths and injuries, including cardiac arrest and stroke.

Hagens Berman has also filed suits against Fresenius Medical Care North America (FMC) ("Fresenius"), the company who manufactured and distributed the two products. According to those lawsuits, an internal memo dated Nov. 4, 2011, reveals that Fresenius knew of the dangers associated with GranuFlo and NaturaLyte, two dialysis products, far in advance of informing the FDA. Moreover, the complaints allege that Fresenius made adjustments at its own clinics to reduce the impact on patients, showing it was aware of the problem.

The suits seek to represent patients who suffered cardiac arrest, stroke, respiratory issues or a litany of other health problems linked to the use of GranuFlo and NaturaLyte, both of which were recalled by the FDA on March 29, 2012.

Patients, former patients or their surviving families who believe they suffered from cardiac, stroke or other adverse events associated with the products are encouraged to contact Hagens Berman attorneys. You can reach an attorney by calling 888-381-2889 or by emailing Fresenius@hbsslaw.com.

According to Steve Berman, managing partner of Hagens Berman, DaVita shares the blame, even though Fresenius manufactured and distributed the products. "Even before the FDA stepped in, our medical experts all conclude that DaVita should have recognized that its patients using the two products showed wild swings in their bicarbonate levels, a clear indication that they were at a much higher risk of cardiac arrest."

Berman also noted that DaVita failed to recognize trends in the number of complications and deaths after dialysis treatments. "Even had the company overlooked the trends relating to bicarbonate levels, we would expect that the high number of complications and deaths would have alerted them that something was amiss."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs